Regarding the microsatellite status, Williams et al. [143] showed that the combination of irinotecan with niraparib, a potent PARP1/2I, in either MSI or MSS CRC cells, synergistically enhanced the anti-tumor effects of both agents either in vitro or in vivo [143]. This evidence concerns the gene PARP1 and colorectal carcinoma.